Motexafin gadolinium in the treatment of brain metastases - Wikidata - awgldk - TriplyDB

Motexafin gadolinium in the treatment of brain metastases

Motexafin gadolinium in the treatment of brain metastases

http://www.wikidata.org/entity/Q28285963

about

Mitochondria as a target in treatment Bromines on N-allyl position of cationic porphyrins affect both radio- and photosensitizing properties.JS-K, a nitric oxide prodrug, has enhanced cytotoxicity in colon cancer cells with knockdown of thioredoxin reductase 1 A Benzothiazole Derivative (5g) Induces DNA Damage And Potent G2/M Arrest In Cancer Cells Motexafin gadolinium: a novel radiosensitizer for brain tumors.Gliomas: Motexafin Gadolinium-enhanced Molecular MR Imaging and Optical Imaging for Potential Intraoperative Delineation of Tumor Margins.Magnetic resonance imaging (MRI) contrast agents for tumor diagnosis.Current State of Metal-Based Drugs for the Efficient Therapy of Lung Cancers and Lung Metastases.Neuroprotective effect of gadolinium: a stretch-activated calcium channel blocker in mouse model of ischemia-reperfusion injury.Selenoproteins in Tumorigenesis and Cancer Progression.

P2860

Q28382780-48E5FF31-53CA-483A-AD78-B17C4D63736C Q33413106-CC0564D4-5A0C-47E8-8A88-1665F6B23C35 Q33526346-E7345261-8197-4404-98B0-F5F03A36E8E8 Q33747092-BFBFDAAC-EA3D-482C-A390-3C0D373C8618 Q36842747-5F8E9A01-F7B1-49B5-94AC-877501FDDBB8 Q36852115-9E4BE707-90FB-4658-AF01-936030E745DB Q38090392-C07C66E7-5772-45CD-8C20-A3EC20C01D14 Q38669290-41E332DE-369B-44D3-AC6F-4DFE06A53F6F Q44006430-87A58357-89F4-4FEB-A2E6-D3CB6C7DA5BF Q47622822-ECE7890F-7EDB-481C-B92C-5613C933CB55

P2860

Motexafin gadolinium in the treatment of brain metastases

http://www.wikidata.org/entity/Q28285963

description

2007 nî lūn-bûn

@nan

2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Motexafin gadolinium in the treatment of brain metastases

@ast

Motexafin gadolinium in the treatment of brain metastases

@en

Motexafin gadolinium in the treatment of brain metastases

@nl

type

label

Motexafin gadolinium in the treatment of brain metastases

@ast

Motexafin gadolinium in the treatment of brain metastases

@en

Motexafin gadolinium in the treatment of brain metastases

@nl

prefLabel

Motexafin gadolinium in the treatment of brain metastases

@ast

Motexafin gadolinium in the treatment of brain metastases

@en

Motexafin gadolinium in the treatment of brain metastases

@nl

P1433

Q28285963-A414E7ED-22E7-43AD-ADA9-6D1EE4A05589

P1476

Q28285963-4C0F2BC6-0028-4F9E-AD5C-B3180C136D95

P2093

Q28285963-35F369FC-599A-4384-8912-D3130F67B3A6

Q28285963-94D646FF-8CFC-4E85-AA47-D708EF9FB2BE

P2860

Q28285963-23A505DE-3CD0-4C7C-9729-DBEFA7AB0F23

Q28285963-32A1E829-1A05-4344-AE18-C5F342CEC54A

Q28285963-46955D30-7BAB-4A8B-86C6-B6FF178D2885

Q28285963-4BD7E726-8A29-492D-B426-56A5E570C04A

Q28285963-4DA84D67-9B33-472A-8470-840CD6AB88EC

Q28285963-54B096B6-A0A1-43B2-B4B7-B449013F0BF1

Q28285963-696CC6F4-3600-4C0B-8913-4B842A3C1293

Q28285963-70E52D21-7933-43D4-8B67-DD8E26B4366D

Q28285963-73635369-8780-4EB0-95CF-3D6ECC656F22

Q28285963-7AC0B1B3-A44C-42AA-9097-DA86D2A88299

P304

Q28285963-798471DB-F034-434A-ACB1-3D02FA89A32E

P31

Q28285963-FC3AAAE8-B542-4323-A873-808F693B3EA1

P356

Q28285963-253F188E-01EA-4944-8B59-71CD4CAAB8BA

P407

Q28285963-7FAEC92F-0156-4E82-8EF6-52C2B6C7536A

P433

Q28285963-490CB96D-7F57-4FA2-93BD-36079112BB47

P478

Q28285963-70C9E08B-0189-465B-95DF-E25D49630DE6

P577

Q28285963-86F7657A-33DE-46E0-9D12-11CE5B773429

P698

Q28285963-A5A6CD0A-E80E-498D-96FA-BF0B1593125B

P921

Q28285963-B5AF5D13-15FF-469E-80B1-EFCA3AAA3724

P356

14656566.8.3.351

P1433

Expert Opinion on Pharmacotherapy

P1476

Motexafin gadolinium in the treatment of brain metastases

@en

P2093

Gregory M Richards

http://www.w3.org/2001/XMLSchema#string

Minesh P Mehta

http://www.w3.org/2001/XMLSchema#string

P2860

Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase

Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points.

RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database.

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.

Identification of prognostic factors in patients with brain metastases: a review of 1292 patients.

Stereotactic radiosurgery for four or more intracranial metastases.

Role of radiosurgery in the management of central nervous system metastases.

Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.

Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.

Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors.

P304

351-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.8.3.351

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2007-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17266469

http://www.w3.org/2001/XMLSchema#string

P921